Why Insured Patients Can Still Overpay for Generic Drugs
Cost Plus Drugs expected uninsured customers to benefit most, but discovered that its cash prices were often lower than insured patients' co-pays. Cuban argues that medicine pricing affects people across income levels and cites research estimating large potential Medicare savings on only a small subset of available drugs.
- Insurance does not guarantee the lowest purchase price
- A cash price below the co-pay saves insured patients money
- The affordability problem extends beyond uninsured consumers
- Institutional purchasing could amplify the savings
“if Medicare bought from us instead of where they buy now it would say $3.6 billion a year and that's just 77 drugs”
“people with insurance were more often than not cheaper than people's co-pays.”